TickerTalks
Browse all tickers →
TickerTalks›$CAPR
CACAPR

Capricor Therapeutics, Inc.

$CAPR·$515M·Biotechnology·Healthcare
$8.10+4.5%YTD-72.2%1Y+8.0%
Price updated 3h ago·X counts updated 3d ago
CACAPR
$CAPRCapricor Therapeutics, Inc.
$8.10+4.52%615 posts0.9×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $CAPR on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

615X posts · last 7 days
Sep 21Oct 4
Chatter Meter
0.9×
QuietNormal · 1×Loud

How loud $CAPR's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-09-11

Capricor Therapeutics is bullish on X — 'This is what The Lancet said on PUL — how we don't get FULL APPROVAL I don't know,' PPMD webinar and two weeks of investor events, and $15-$18 pre-PDUFA target. Waiting for the moment framing dominates; risk-management context around bio-LLM missteps.

Read what X is saying about $CAPR

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $CAPR — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-10-03

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Capricor pre-PDUFA on PUL for DMD — the setup is binary and the valuation is at 69% drawdown.

Capricor Therapeutics is a clinical-stage biotech whose lead asset is deramiocel (CAP-1002) for Duchenne muscular dystrophy — a potentially-first-approved cell therapy for DMD cardiomyopathy. The 2026 drawdown reflects regulatory uncertainty and the broader biotech degrossing.

  • The P&L is pre-revenue: zero quarterly revenue with EPS of -$0.59 and trailing prints missing Street estimates by 19% and 7% — this is a cash-burn-until-approval setup where the stock trades on the FDA decision and the subsequent commercial launch economics.
  • The specific catalysts are near-term: PPMD webinar coverage, 'two weeks of investor events,' and a $15-$18 pre-PDUFA target framework — plus the recent Lancet publication of PUL data makes the full-approval case explicit, which is the kind of validation that typically precedes a positive FDA action.

At 16% of its 52-week range and 61% below the 200-day, this is a deep-drawdown biotech catalyst coil. A positive PDUFA decision or any accelerated-approval signal plus Nov 9 earnings cash-runway clarity is the trigger for a sharp move toward the $15 target; a complete response letter or any safety signal is the catastrophic invalidation.

Agrees with X sentimentThe Lancet-PUL-data citation and the specific PDUFA target framework are grounded on real regulatory optionality. The 'how we don't get full approval' bull voice is confident but still appropriately framed around real uncertainty.

What to watch: PDUFA decision date and Nov 9 Q3 earnings — regulatory decision outcome, cash runway, commercial-launch planning, and any safety-signal update. Positive PDUFA is the trigger; CRL is the invalidation.

On the calendar: 2026-11-09 — Q3 earnings

event ahead 30dpdufa catalyst

Read the AI verdict on $CAPR

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing cardiosphere-derived cell and exosome therapies for Duchenne muscular dystrophy and rare cardiac diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $CAPR.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $CAPR

Neutral — Clinical-stage biotech developing cardiosphere-derived cell and exosome therapies for Duchenne muscular dystrophy and rare cardiac diseases.

Top industry ETF

$IBBiShares Biotechnology ETF
+19.7%YTD
+34.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-11.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-40.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-10.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-59.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 14, 2026$-0.70$-0.59-18.9%
Q1 2026May 12, 2026$-0.59$-0.55-7.3%
Q4 2025Mar 12, 2026$-0.62$-0.51-21.6%
Q3 2025Nov 10, 2025$-0.54$-0.540.0%
Next earningsMon, Nov 9·consensus EPS $-0.14

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.59$-40.0M
Q4 FY25$0-100.0%——$-0.62$-28.7M
Q3 FY25$0-100.0%——$-0.54$-23.7M
Q2 FY25$0-100.0%——$-0.57$-21.6M

Forward consensus

5-year forecast · up to 8 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$92.2M$1.9M – $260.9M-$1.54-$2.48 – $1.537
FY27$83.8M$7.5M – $164.5M-$1.49-$3.56 – $0.788
FY28$313.4M$19.4M – $724.0M$0.16-$2.27 – $3.865
FY29$464.0M$28.7M – $1.1B-$0.03-$0.09 – $0.012
FY30$483.9M$29.9M – $1.1B$1.36-$0.30 – $3.682

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.13%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+3.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-65.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 48.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today6.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.535-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 25Karen KrasneyEVP, GENERAL COUNSEL24.1K sh$732KSellJun 25Anthony BergmannCFO24.1K sh$732KSellJun 24Karen KrasneyEVP, GENERAL COUNSEL400 sh$12KSellJun 24Anthony BergmannCFO400 sh$12KSellMay 1Anthony BergmannCFO25.0K sh$793KSellMay 1Karen KrasneyEVP, GENERAL COUNSEL25.0K sh$793K
+ 11 other (10 exempts · 1 award) in window

See when $CAPR insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementJul 148-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation
AI summary

Capricor Therapeutics (CAPR) — 8-K (Items 1.01, 2.03) disclosing a lease for approximately 171,000 sq ft at 9625 Towne Centre Drive, San Diego, for a combined HQ and manufacturing facility. The 138-month lease is contingent on FDA approval of a Capricor product or, if later, December 31, 2026. Material — major facility commitment that scales with anticipated FDA approval timeline.

8-KShareholder voteJun 88-K — Item 5.07: Shareholder vote
AI summary

Capricor Therapeutics held its 2026 Annual Meeting on June 4, 2026 with 43.8 million shares present. Shareholders elected all eight director nominees (Linda Marbán, Frank Litvack, David Musket, George Dunbar, Karimah Es Sabar, Paul Auwaerter, Philip Gotwals, Michael Kelliher); ratified Rose, Snyder & Jacobs as auditor; approved executive compensation; set annual say-on-pay frequency; and approved officer exculpation provisions. All proposals passed routinely.

3New insider — initial holdingsMay 283
AI summary

Capricor Therapeutics received an initial Form 3 from Michael T. Maurer, newly appointed Chief Commercial Officer, as of May 25, 2026. No common shares are reported in Table I; derivative securities are likely in Table II but not fully visible. Routine Section 16(a) officer disclosure with no market impact.

8-KPress release / Reg FDMay 78-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
+ 13 other (5 13Gs · 4 routine 8-Ks · 2 10-Qs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcriptseekingalpha.com·5h agoCapricor Highlights Two-Year Deramiocel Data as FDA Decision Nearsmarketbeat.com·7h agoCapricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congressglobenewswire.com·3d agoInflation Breather Could Help Stocks Finish Q3 Strongschaeffersresearch.com·8d agoCAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026businesswire.com·10d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$KOD$MRNA$IOVA$ARCT$IBRX$VKTX$NWBO$QURE
Voices on X · last 7 days

No standout posts about $CAPR on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport